Inpatient Initiation of β-blockade Plus Nurse Management in Vulnerable Heart Failure Patients: A Randomized Study
Abstract
Background
Predischarge β-blocker initiation in hospitalized patients with heart failure due to reduced left ventricular ejection fraction (LVEF) is safe and improves adherence; improved outcomes with this approach have not been demonstrated in a randomized trial. This study compared 6-month rehospitalization rates among patients assigned to predischarge β-blockade coupled with postdischarge nurse management (intervention) versus usual care.
Methods and Results
We randomized 64 patients with an LVEF ≤0.40 to low-dose carvedilol coupled with nurse management or usual care. The nurse manager saw patients within 2 weeks of discharge, then biweekly until stable. Baseline characteristics reflected a vulnerable population (80% uninsured, 72% minorities, 80% unemployed or disabled), as did heart failure etiology (28% substance abuse, 27% ischemic, 19% hypertension, 17% idiopathic). Mean baseline LVEF was 0.23 in both groups. Among intervention patients at 6 -months, β-blocker utilization was higher (96 vs. 48%, P < .001), mean New York Heart Association class improved (–1.44 vs. –0.77, P = .01), and total heart failure rehospitalizations were reduced by 84% (3 vs. 19, P = .02). A trend toward improved LVEF was also observed (+16 vs. +11 units, P = .17).
Conclusion
Inpatient β-blocker initiation coupled with nurse management improved outcomes among sociodemographically disadvantaged heart failure patients. Our results support a practice shift toward inpatient β-blocker initiation with structured outpatient follow-up.
Key Words: Carvedilol, disease management, hospitalization, guidelines
To access this article, please choose from the options below
MK and CSL report having received consulting fees from GlaxoSmithKline and AstraZeneca.
The trial was an investigator initiated study funded by Glaxo Smith Kline; Philadelphia, PA. The sponsor had no role in the conception, design, or implementation of the trial. Interpretation and analysis of all data were done solely by the clinical investigators. Clinicaltrials.gov identifier: NCT00381030.
PII: S1071-9164(07)01167-0
doi:10.1016/j.cardfail.2007.12.008
© 2008 Elsevier Inc. All rights reserved.
